Literature DB >> 25290812

Sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA could effectively deliver siRNA to the liver.

Yoshiyuki Hattori1, Shohei Arai2, Ryou Okamoto2, Megumi Hamada2, Kumi Kawano2, Etsuo Yonemochi2.   

Abstract

In this study, we developed novel siRNA transfer method to the liver by sequential intravenous injection of anionic polymer and cationic liposome/cholesterol-modified siRNA complex (cationic lipoplex). When cationic lipoplex was intravenously injected into mice, the accumulation of siRNA was mainly observed in the lungs. In contrast, when cationic lipoplex was intravenously injected at 1 min after intravenous injection of poly-L-glutamic acid (PGA) or chondroitin sulfate C (CS), siRNA was accumulated in the liver. In terms of suppression of gene expression in vivo, apolipoprotein B (ApoB) mRNA in the liver and low-density-lipoprotein (LDL) and very low-density-lipoprotein (VLDL) cholesterol level in serum were reduced at 48 h after single sequential injection of PGA or CS plus cationic lipoplex of cholesterol-modified ApoB siRNA. Furthermore, sequential injections of PGA plus cationic lipoplex of cholesterol-modified luciferase siRNA could reduce luciferase activity in tumor xenografts bearing liver metastasis of human breast tumor MCF-7-Luc. From these findings, sequential injection of anionic polymer and cationic lipoplex of siRNA might produce a systemic vector of siRNA to the liver.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anionic polymer; Chondroitin sulfate; Liposome; Poly-l-glutamic acid; siRNA delivery

Mesh:

Substances:

Year:  2014        PMID: 25290812     DOI: 10.1016/j.ijpharm.2014.09.059

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

Review 1.  Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.

Authors:  Deidra M Ward; Aaliyah B Shodeinde; Nicholas A Peppas
Journal:  Adv Healthc Mater       Date:  2021-05-11       Impact factor: 11.092

2.  Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA.

Authors:  Yoshiyuki Hattori; Takuto Kikuchi; Kei-Ichi Ozaki; Hiraku Onishi
Journal:  Exp Ther Med       Date:  2017-08-28       Impact factor: 2.447

3.  Therapeutic effects of protein kinase N3 small interfering RNA and doxorubicin combination therapy on liver and lung metastases.

Authors:  Yoshiyuki Hattori; Takuto Kikuchi; Mari Nakamura; Kei-Ichi Ozaki; Hiraku Onishi
Journal:  Oncol Lett       Date:  2017-08-25       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.